TLTungming Leung

Tungming Leung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tungming Leung has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative treatment outcomes of non-extended-spectrum beta-lactamase, ceftriaxone-non-susceptible, enterobacterales bacteremia with piperacillin/tazobactam, cefepime, carbapenem, or other antibiotic treatment

    by Esther Kanner, Sumeet Jain, Pranisha Gautam-Goyal, Aya Haghamad, Tungming Leung, Vincent Streva, Jamie Lemon, Patricia Saunders-Hao

    Objective: To evaluate outcomes in patients with ceftriaxone-non-susceptible, non-extended-spectrum beta-lactamases (ESBL), Enterobacterales bacteremia treated with carbapenem and non-carbapenem treatment options. Methods: This pilot retrospective chart review evaluated adult patients admitted between January 2021 and November 2024 with a bacteremia caused by a non-ESBL, ceftriaxone-non-susceptible, piperacillin/tazobactam-sensitive, cefepime-sensitive, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae , or Proteus mirabilis . Patients were stratified into 3 groups depending on the administered targeted treatment (cefepime or piperacillin/tazobactam vs carbapenem vs other). Results: Of the 76 patients who were screened, 40 patients were analyzed. There were 28 patients in the cefepime or piperacillin/tazobactam group, 8 patients in the carbapenem group, and 4 patients in the other antibiotics group. The median age of the cohort was 77 years, most patients were female, and 30% of patients were in septic shock. The most common source of infection was genitourinary (63%). Thirty-day mortality was 3.8% in the cefepime or piperacillin/tazobactam group, 14.3% in the carbapenem group, and 0% in the other antibiotic group ( P = .611). There was no significant difference in any of the secondary outcomes. Conclusions: In this pilot retrospective chart review, there was no difference between carbapenem and non-carbapenem treatment for ceftriaxone-non-susceptible, non-ESBL Enterobacterales bacteremia. Better understanding of the resistance mechanisms and collaboration with other healthcare systems to increase sample size may help assess optimal treatment of these organisms.